%PDF-1.3
%
10 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 131>>stream
xA =e6'P1i`PC}a32Y3
(qJ䣣^sLn=!$)NS'0 LKzX}FJVDZ9OUXŪZPo"&
endstream
endobj
12 0 obj
<>stream
2022-06-11T14:33:35+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2022-08-03T08:04:49-07:00
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
application/pdf
GENBIO-2022-0011-ver9-Harris_2P 262..270
uuid:9bae1c81-4ec2-4b5d-98b1-6484bc118cca
uuid:11c3fb87-0537-42c6-880f-6c294518d150
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
32 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
9.4646 0 0 9.4646 47.8488 195.8173 Tm
0 0 0 rg
0 Tc
0 Tw
[(exhaustion)-474.5(of)-479.8(the)-476.9(CAR-T)-479(cells,)-476.8(or)-478.8(other)-482.4(mechanisms)-475.4(lead)-482.2(to)]TJ
0 -1.21 TD
[(eventual)-297.4(resistance)-303.5(and)-299.8(relapse.)]TJ
.9943 -1.216 TD
[(CAR-T)-263.4(cells)-266.5(are)-262.4(most)-263(often)-267.8(engineered)-256.6(by)-263.8(lentivirus)-269.2(transduc-)]TJ
-.9943 -1.21 TD
[(tion)-284.8(to)-281.1(express)-288.3(an)-286.8(antibody)-286.3(single-chain)-283.1(variable)-285(domain)-284.2(\(scFv\))]TJ
T*
[(fragment)-383.9(or)-382.9(a)-389.5(receptor)-383.4(binding)-385.9(domain)-386(as)-383.9(the)-387(afnity)-385.5(ligand,)]TJ
T*
[(linked)-461(to)-466.8(an)-466.5(intracellular)-469(signaling)-465.9(domain)-463.9(derived)-469.9(from)-462.9(the)]TJ
T*
[(TCR)-312.8(\(CD3zeta\))-314.7(and)-317.8(a)-311.7(second)-315.4(costimulatory)-320.9(domain,)-314.8(usually)-316.6(de-)]TJ
T*
[(rived)-333.9(from)-343.1(CD28)-333.7(or)-341(4-1BB)-339.4(\(CD137\))-339.8(\(see)-336.6(Fig.)-340(2)-334.6(for)-337.5(the)-339.1(structure)]TJ
T*
[(of)-342(a)-341.6(typical)-342.8(CAR\).)]TJ
7.0982 0 0 6.3091 116.5606 108.3401 Tm
(5)Tj
9.4646 0 0 9.4646 123.4204 104.1448 Tm
[(In)-339.1(contrast)-345.7(to)-341(B)-345.5(cell)-338.1(malignancies,)-346.9(there)-337.7(are)]TJ
-7.9847 -1.21 TD
[(very)-345.5(few)-342.9(examples)-350.8(wherein)-341.7(CAR-T)-347.2(cells)-350.4(have)-344(led)-350.3(to)-347(clinical)-345.6(re-)]TJ
T*
[(sponses)-224(in)-231.3(solid)-230.3(tumor)-226.3(indications.)-231.6(The)-226(most)-227.1(notable)-229.3(exceptions)]TJ
T*
[(are)-280.3(clinical)-279.8(remissions)-281.1(of)-282.1(gliomas)-282(induced)-284.8(by)-281.8(locoregionally)-280.7(de-)]TJ
T*
[(livered)-299.8(CAR-T)-299.3(cells)-302.5(targeting)-297.1(IL-13Ra2)-300.5(or)-305(GD2.)]TJ
7.0982 0 0 6.3091 229.2094 62.5323 Tm
(6,7)Tj
/F2 1 Tf
10.4607 0 0 10.4607 310.8472 195.1369 Tm
[(Increasing)-298.3(CAR-T)-298.3(cell)-298.9(persistence)-301.8(and)-300.8(efcacy)]TJ
/F5 1 Tf
9.4646 0 0 9.4646 310.8472 183.2881 Tm
[(There)-326.5(is)-334.4(great)-328.8(interest)-332.2(in)-327.1(further)-336.6(engineering)-327(CAR-T)-329.3(cells)-332.4(to)-329(in-)]TJ
T*
[(crease)-190.2(efcacy)-196.4(and)-192(durability)-196(especially)-196.9(in)-195.4(the)-189.4(context)-194.4(of)-198.3(treating)]TJ
T*
[(solid)-272.3(tumors.)]TJ
7.0982 0 0 6.3091 361.8141 164.5795 Tm
(5)Tj
9.4646 0 0 9.4646 368.1637 160.3842 Tm
[(This)-293.7(includes)-294.7(engineering)-297(the)-291.2(CARs,)-294.6(or)-293.1(engineer-)]TJ
-6.0559 -1.21 TD
[(ing)-200.4(the)-201.4(cells)-206.6(to)-203.2(make)-199.8(anti-PD1)-204.6(antibodies,)-206(express)-204.4(cytokines)-205.1(con-)]TJ
T*
[(stitutively,)-295.4(and)-293.8(express)-294.2(chemokine)-295.7(receptors)-299.9(such)-293.3(as)-294(CCR2)-294.8(that)]TJ
T*
[(attract)-218.1(infused)-218.5(CAR-T)-221.4(cells)-218.6(to)-221.2(tumor-secreted)-221.8(cytokines.)]TJ
7.0982 0 0 6.3091 526.3936 130.2236 Tm
(810)Tj
9.4646 0 0 9.4646 542.8912 126.0283 Tm
(CAR-)Tj
-24.5171 -1.216 TD
[(T)-259.7(cell)-254.2(exhaustion,)-259.5(identied)-258.9(by)-257.8(the)-261.3(expression)-260.1(of)-258.2(multiple)-256.8(inhib-)]TJ
0 -1.21 TD
[(itory)-352.2(receptors)-359.8(including)-353.9(PD-1,)-355.7(TIM-3,)-358.2(and)-353.7(LAG-3,)-352.8(is)-358.4(common.)]TJ
7.0982 0 0 6.3091 558.2549 107.3197 Tm
(5)Tj
9.4646 0 0 9.4646 310.8472 91.6157 Tm
[(One)-273.6(reason)-277.9(is)-274.5(tonic)-275(signaling)-274.2(by)-275.8(the)-273.2(CAR)-275.7(even)-275.1(without)-274.1(antigen,)]TJ
T*
[(especially)-298.7(CARs)-300(harboring)-303.6(CD28)-303.7(signaling)-298.2(domains.)]TJ
1.0003 -1.21 TD
[(To)-311.8(function)-316.6(optimally,)-319.6(CARs)-317.9(need)-311.9(high-density)-313.7(expression)-320(of)]TJ
-1.0003 -1.21 TD
[(the)-321.2(corresponding)-332.2(antigens)-324.4(on)-320.6(a)-329.7(target)-324.3(cell.)-326.8(However,)-327.9(this)-322.9(can)]TJ
ET
q
1 i
60.265 705.316 m
549.411 705.316 l
549.411 360.737 l
60.265 360.737 l
W n
q
489.531 0 0 344.579 60.265 360.737 cm
/Im2 Do
Q
Q
BT
/F4 1 Tf
9.9626 0 0 9.9626 47.8488 342.822 Tm
[(FIG.)-337.7(1.)-1001.9(T)-301.2(cell-base)-13.3(d)-300.4(thera)-10.9(peutics)-306.7(for)-307.7(cance)-9.6(r.)]TJ
/F3 1 Tf
8.9663 0 0 8.9663 251.1495 342.822 Tm
[(Most)-302.9(therapies)-303.5(start)-304.7(with)-296(peripheral)-308.9(blood)-297.3(mononuclear)-303.1(cells)-302(\(PBMC\))-303.1(obtained)-302.3(from)]TJ
-22.674 -1.3341 TD
[(blood)-297.3(draws)-307.3(or)-297.2(leukapheresis.)-305.1(CAR-T)-305.9(cells)-295.7(are)-306.8(then)-300.5(activated)-303.9(and)-302(gene)-296.8(engineered)-303.3(to)-298.8(express)-305(a)-299.1(CAR)-302.5(composed)-303.9(of)-296.5(separate)-304.7(tumor)-300.8(binding)]TJ
T*
[(and)-295.7(signaling)-303.3(domains.)-307.6(TCR-T)-298.1(cells)-302(are)-300.5(gene)-303.2(edited)-301.6(to)-298.8(express)-305(monoclonal)-304(TCR)]TJ
/F8 1 Tf
32.1457 0 TD
(a)Tj
/F3 1 Tf
.7967 0 TD
(and)Tj
/F8 1 Tf
1.821 0 TD
(b)Tj
/F3 1 Tf
.8536 0 TD
[(chains,)-300.4(which)-300.2(then)-300.5(associate)-309.6(with)-296(the)-300.3(endogenous)]TJ
-35.617 -1.3341 TD
[(TCR)-294.7(signalosome.)-306.3(To)-300.9(make)-299.3(MTCs,)-304(PBMCs)-301.1(are)-300.5(separated)-307.4(into)-299.6(monocytes)-305.6(and)-302(T)-294.4(cells.)-306.8(The)-296.1(monocytes)-305.6(are)-300.5(differentiated)-305.7(into)-299.6(DCs)-300.6(that)-302.2(are)]TJ
T*
[(treated)-301.5(with)-296(libraries)-307.8(of)-296.5(peptides)-307.1(derived)-301.9(from)-300.1(targeted)-304.3(TAAs)-300.9(to)-298.8(present)-300.9(those)-303.2(on)-297.4(their)-307.2(surface.)-298.6(The)-302.4(T)-300.7(cells)-302(are)-300.5(added)-302.6(back)-302.5(and)-302(TAA-reactive)]TJ
T*
[(T)-294.4(cells)-302(are)-306.8(expanded)-301(and)-302(primed)-302.1(by)-299.2(the)-300.3(DCs)-300.6(to)-298.8(become)-306.1(MTCs.)-297.7(Applying)-304.9(recently)-301(developed)-306.5(advanced)-303.1(technologies,)-306.8(the)-300.3(T)-294.4(cells)-302.1(can)-304.8(be)]TJ
0 -1.3278 TD
[(enhanced)-298.3(for)-302.7(improved)-304.2(function)-303(and)-302(expansion)-297.5(in)-304.3(patients)-303.6(by)-299.2(tethering)-300.5(supporting)-302.7(cytokines)-303.7(such)-304.1(as)-301.8(IL-15)-302.7(or)-297.2(IL-12)-302.7(to)-298.8(them.)]TJ
6.7246 0 0 5.9768 498.7274 275.0739 Tm
(4648)Tj
8.9663 0 0 8.9663 517.6628 271.1054 Tm
[(TILs)-306.1(are)]TJ
-52.398 -1.3341 TD
[(generated)-298.1(from)-300.1(fragments)-304.2(of)-302.9(tumor)-300.8(biopsies)-304.8(that)-302.2(are)-300.5(rst)-302.8(cultured)-299.8(with)-302.3(high)-300.9(doses)-300.8(of)-302.9(IL-2)-301.2(to)-298.8(expand)-303(tumor-resident)-305.1(T)-300.7(cells)-302(that)-302.2(react)-301.3(with)]TJ
T*
[(tumor)-300.8(antigens)-302.2(presented)-298.9(in)-304.3(the)-300.3(tumor)-300.8(fragment.)-299.9(Expanding)-308.5(T)-300.8(cells)-295.7(are)-306.8(expanded)-300.9(further)-304.1(and)-302(pooled)-298.9(to)-298.8(generate)-301.7(oligoclonal)-304.3(TIL)]TJ
T*
(products.)Tj
6.7246 0 0 5.9768 80.9575 239.1873 Tm
[(5,23,3)-11.4(5,50)]TJ
8.9663 0 0 8.9663 109.644 235.2188 Tm
[(CAR,)-300.9(chimeric)-302.2(antigen)-299.5(receptor;)-302.1(DCs,)-305.3(dendritic)-300(cells;)-306.8(MTC,)-301.3(multi-tumor)-305.6(antigen)-299.5(targeted)-304.3(T)-300.7(cells;)-300.4(TAA,)-302.9(tumor-associated)]TJ
-6.892 -1.3341 TD
[(antigen;)-297.9(TCR,)-305.7(T)-294.4(cell)-305.6(receptor;)-302.1(TIL,)-301.7(tumor-inltrating)-305.7(lymphocytes.)-306.5(Created)-300.7(with)-302.3(BioRender.com)]TJ
/F4 1 Tf
9.9626 0 0 9.9626 47.8488 753.8455 Tm
[(T)-301.2(CELL)-302.9(THER)-8.2(APIES)-308(FOR)-305.9(CANCER)]TJ
49.9403 0 TD
(263)Tj
ET
endstream
endobj
35 0 obj
<>stream
Adobe d
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz m !1AQa"q2#BRbr3$4CS%cs5DT
&6E'dtU7()euFVfvGWgw8HXhx9IYiy*:JZjz ? N*S6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثؑp@rh:fZ͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثbHM1UX-.`*2/Q
ܱx⭍Z%%IVNhGQNUJMmZlH"2GjCf]vlUٱWf]vlUٱWf]vlU]bظ#ҽ>y&"dvZ&
4Q7Ve]2Mo!`x좾9`B/5.?T8c7z}|nFM+^Nt_?EZ4m款4{g=ڽpJk vy{Btդq؎r|
EsBr(H͊vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWf]vlUٱWdϞy_._Efe@J 벻2\cC5qc!Ev"\K
n̵^ɭ(ž-%D&:rcg>:vu8/ܑƱK]Mo`
r.pe/ʚx.%=˝j+Zf7e i %wZ&soݘr͢? PIچHUlp ~ŵqfΌW`*ثb͊6*ثb͊6*ثb͊ ߘWD!F]&oHÐ;lvV0l-7m1ʺh6 ytѴ=^uZWWcialWVݙnaDO\x>GIG[7Y++Do0ZEW_ܵU+$ziŽR*8,iS@:滵
#nU ;}; 4]nvCF`R_wv-
1@
bL?x}2)S͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثt6*fZ͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊)EDXmays- |#a5'1/r.- JHV foZ'6(HŜd
KY19G*Sц;H|ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ثb͊6*ث~myK\/,U^b
Ȱ$9NlRWGk?'Ckz鯤=ɏU7um
Ԗ2QsGɐikpGxu>هyc{:lzcVr$GPմG\TGk+i@ UM*qtLUPjGs,RG{_S=n DҴ-